AorTech International plc, together with its subsidiaries, focuses on the commercialization of its biomedical polymer technology, components, and medical devices in the United Kingdom.
+ 2 more risks
Flawless balance sheet with limited growth.
Share Price & News
How has AorTech International's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AOR's share price has been volatile over the past 3 months.
7 Day Return
GB Medical Equipment
1 Year Return
GB Medical Equipment
Return vs Industry: AOR exceeded the UK Medical Equipment industry which returned -1.4% over the past year.
Return vs Market: AOR exceeded the UK Market which returned -22.7% over the past year.
Price Volatility Vs. Market
How volatile is AorTech International's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StIs AorTech International plc's (LON:AOR) CEO Paid Enough Relative To Peers?
1 month ago | Simply Wall StImagine Holding AorTech International (LON:AOR) Shares While The Price Zoomed 417% Higher
3 months ago | Simply Wall StHere's Why We're Not Too Worried About AorTech International's (LON:AOR) Cash Burn Situation
Is AorTech International undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate AOR's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate AOR's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: AOR is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: AOR is unprofitable, so we can't compare its PE Ratio to the UK market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AOR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AOR is overvalued based on its PB Ratio (3.6x) compared to the GB Medical Equipment industry average (2.9x).
How is AorTech International forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AOR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AOR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AOR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AOR's revenue (61.4% per year) is forecast to grow faster than the UK market (2.6% per year).
High Growth Revenue: AOR's revenue (61.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AOR's Return on Equity is forecast to be high in 3 years time
How has AorTech International performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AOR is currently unprofitable.
Growing Profit Margin: AOR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AOR is unprofitable, and losses have increased over the past 5 years at a rate of -4.5% per year.
Accelerating Growth: Unable to compare AOR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AOR is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-7.4%).
Return on Equity
High ROE: AOR has a negative Return on Equity (-19.07%), as it is currently unprofitable.
How is AorTech International's financial position?
Financial Position Analysis
Short Term Liabilities: AOR's short term assets (£2.6M) exceed its short term liabilities (£80.0K).
Long Term Liabilities: AOR has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: AOR is debt free.
Reducing Debt: AOR has not had any debt for past 5 years.
Inventory Level: AOR has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if AOR's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AOR has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: AOR has sufficient cash runway for 2.7 years if free cash flow continues to reduce at historical rates of -18.1% each year.
What is AorTech International's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AOR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate AOR's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AOR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AOR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AOR's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Bill Brown (55yo)
Mr. William Donald Brown, also known as Bill, serves as the Finance Director and CEO at AorTech International plc. Mr. Brown serves as a Fund manager at F&C Asset Management plc. Mr. Brown was a Partner of ...
CEO Compensation Analysis
Compensation vs Market: Bill's total compensation ($USD223.33K) is below average for companies of similar size in the UK market ($USD332.86K).
Compensation vs Earnings: Bill's compensation has increased whilst the company is unprofitable.
|CEO, Executive Chairman & Finance Director||no data||UK£180.02k||3.45% £354.7k|
|Director of Clinical Marketing & Executive Director||3.42yrs||UK£60.38k||0.13% £13.1k|
|Non-Executive Director||14.33yrs||UK£18.00k||4.37% £449.2k|
|Non-Executive Director||1.75yrs||UK£14.55k||no data|
|Non-Executive Director||1.75yrs||UK£14.50k||0.23% £23.3k|
|Non-Executive Director||1.75yrs||UK£14.50k||0.11% £11.7k|
Experienced Board: AOR's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 75.4%.
AorTech International plc's company bio, employee growth, exchange listings and data sources
- Name: AorTech International plc
- Ticker: AOR
- Exchange: AIM
- Founded: 1996
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: UK£10.281m
- Shares outstanding: 14.69m
- Website: https://www.aortech.net
Number of Employees
- AorTech International plc
- Springfield House
- Level Two
- KT13 9LZ
- United Kingdom
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|AOR||AIM (London Stock Exchange AIM Market)||Yes||Ordinary Shares||GB||GBP||Feb 1997|
|AOHA||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Feb 1997|
AorTech International plc, together with its subsidiaries, focuses on the commercialization of its biomedical polymer technology, components, and medical devices in the United Kingdom. The company offers Elast-Eon, a bio stable polyurethane material used in long term implantation; and Elast-Eon Carbonate Silicone, a family of biomedical polymers for applications in cardiac pacing leads, orthopedics, and spinal discs, as well as in other applications where the device requires a high level of mechanical performance. It also provides Elast-Eon Reaction Injection Molding products for use in high-precision medical device components. In addition, the company licenses its technology; and offers support services to other medical device companies. AorTech International plc was incorporated in 1996 and is headquartered in Weybridge, the United Kingdom.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/03/30 20:52|
|End of Day Share Price||2020/03/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.